1,099 results on '"Bashey, Asad"'
Search Results
2. Haploidentical vs. sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia
3. Extracorporeal photopheresis (ECP) improves overall survival in the treatment of steroid refractory acute graft-versus-host disease (SR aGvHD)
4. Impact of Graft-Versus-Host Disease on Relapse and Nonrelapse Mortality Following Posttransplant Cyclophosphamide-Based Transplantation
5. Phase 1 study of vibecotamab identifies an optimized dose for treatment of relapsed/refractory acute myeloid leukemia
6. Incidence and impact of community respiratory viral infections in post‐transplant cyclophosphamide‐based graft‐versus‐host disease prophylaxis and haploidentical stem cell transplantation
7. Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant
8. A simple prognostic system in patients with myelofibrosis undergoing allogeneic stem cell transplantation: a CIBMTR/EBMT analysis
9. Improved access to HCT with reduced racial disparities through integration with leukemia care and haploidentical donors
10. Immunosuppression-Free Status at 1 Year after Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide
11. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant
12. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide.
13. Comparing transplant outcomes in ALL patients after haploidentical with PTCy or matched unrelated donor transplantation
14. Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT
15. Myeloablative vs reduced intensity T-cell-replete haploidentical transplantation for hematologic malignancy.
16. Revised HLA-DP TCE-Core Permissiveness Model Better Defines Relapse Risk and Survival following Haploidentical Transplant
17. Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) As a Biomarker of Acute Kidney Injury Requiring Dialysis (AKI-D) in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation (HCT): Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study
18. HLA-DQ G1/G2 Heterodimer Genotype Impacts Relapse and Survival Following Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide
19. Donor Search and Selection Strategy to Facilitate Comparable Transplant Rates across Donor Search Prognosis Groups: A Report from the BMT CTN 1702 Trial
20. Incidence of Mucositis and Effect on Outcomes with Myeloablative/Dose-Intensified Conditioning Regimens for HLA-Haploidentical Allotransplantation
21. Impact of Acute and Chronic Graft-Versus-Host Disease (GVHD) on Non-Relapse Mortality and Survival Following Haploidentical Donor Transplantation.
22. Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study
23. Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission.
24. Autologous Transplantation, Consolidation, and Maintenance Therapy in Multiple Myeloma: Results of the BMT CTN 0702 Trial
25. HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide
26. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma
27. Related donor transplants: has posttransplantation cyclophosphamide nullified the detrimental effect of HLA mismatch?
28. The European Society for Blood and Marrow Transplantation (EBMT) Consensus Guidelines for the Detection and Treatment of Donor-specific Anti-HLA Antibodies (DSA) in Haploidentical Hematopoietic Cell Transplantation
29. Galectin-3 predicts acute GvHD and overall mortality post reduced intensity allo-HCT: a BMT-CTN biorepository study
30. Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation
31. Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors
32. Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia.
33. A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes
34. Differences in Graft-versus-Host Disease Characteristics between Haploidentical Transplantation Using Post-Transplantation Cyclophosphamide and Matched Unrelated Donor Transplantation Using Calcineurin Inhibitors
35. Class II HLA mismatch improves outcomes following haploidentical transplantation with posttransplant cyclophosphamide
36. The Transplant Evaluation Rating Scale predicts overall survival after allogeneic hematopoietic stem cell transplantation
37. Optimal Donor for African Americans with Hematologic Malignancy: HLA-Haploidentical Relative or Umbilical Cord Blood Transplant
38. Prospective phase 2 trial of ixazomib after nonmyeloablative haploidentical peripheral blood stem cell transplant
39. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era
40. Improved Post remission survival of non- favorable risk Acute Myelogenous Leukemia (AML) patients following initial remission induction therapy with FLAG+/-Idarubicin versus 3 + 7 (Anthracycline + Cytarabine)
41. Survival following allogeneic transplant in patients with myelofibrosis
42. Ipilimumab for Patients with Relapse after Allogeneic Transplantation
43. Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor
44. AML-522 COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/MLL1 Rearrangements, NPM1 Mutation), DLBCL, MM, and CLL/SLL (NCT05153330)
45. POSTER: AML-522 COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/MLL1 Rearrangements, NPM1 Mutation), DLBCL, MM, and CLL/SLL (NCT05153330)
46. P-213 COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330)
47. Fludarabine and Total-Body Irradiation Conditioning before Ablative Haploidentical Transplantation: Long-Term Safety and Efficacy
48. Who Is a Better Donor for Recipients of Allogeneic Hematopoietic Cell Transplantation: A Young HLA-Mismatched Haploidentical Relative or an Older Fully HLA-Matched Sibling or Unrelated Donor?
49. HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis
50. The European Society for Blood and Marrow Transplantation (EBMT) consensus recommendations for donor selection in haploidentical hematopoietic cell transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.